Pharma Commercialization Thought Leader Interview Series— Doug Fulling, Precision AQ
We are pleased to present the Thought Leader Interview Series—a collection of one-on-ones presented by the Houlihan Lokey Pharma Commercialization team where we sit down with key thought leaders to discuss emerging themes across the industry. In this Q&A with Doug Fulling (President of Precision AQ), we discuss the company’s rebrand, the critical role value and access plays in the pharma commercialization lifecycle, and other factors that are transforming the industry.
For more information, click here: Pharma Commercialization—Thought Leader Interview Series With Doug Fulling, Precision AQ (hl.com)
Very nice 😊
Mark Martin and Houlihan Lokey thank you for covering Precision AQ’s rebrand and mission to enable access to life-changing medicines for all. It is always a pleasure and honor to be working with your team. #PrecisionAQ #PharmaIndustry #PharmaCommercialization #PrecisionforMedicine #PrecisionValueandHealth #MarketAccess
Strategy, Growth, Leadership - as an entrepreneur, I have an insatiable appetite for finding fresh solutions to unmet needs.
7moDoug, I like how you’ve redefined “access” to include HCP and patient, not just payer comm. Nice move.